Abstract 4817: Preclinical evaluation of a new, non-agonist ADC targetingMET-amplified tumors with a peptide-linked maytansinoid

Volume: 79, Pages: 4817 - 4817
Published: Jul 1, 2019
Abstract
With cancer among the leading causes of death worldwide, the search for better, personalized treatments is imperative. Novel techniques such as next generation sequencing have identified many assayable genetic biomarkers associated with cancer in patient samples. The tyrosine kinase receptor cMet is one such biomarker that is upregulated in various solid tumors and associated with poor prognosis, disease progression and metastasis. While most...
Paper Details
Title
Abstract 4817: Preclinical evaluation of a new, non-agonist ADC targetingMET-amplified tumors with a peptide-linked maytansinoid
Published Date
Jul 1, 2019
Volume
79
Pages
4817 - 4817
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.